Feasibility of Combination Intra-arterial Yttrium-90 and Irinotecan Microspheres in the VX2 Rabbit Model

Overview

Journal Cardiovasc Intervent Radiol

Specialty Cardiology & Vascular Diseases

Date 2020 Jun 14

PMID 32533312

Citations 1

Authors

Andrew C Gordon

Sarah B White

Yihe Yang

Vanessa L Gates

Daniel Procissi

Kathleen R Harris

Zhuoli Zhang

Tianchu Lyu

Xiaoke Huang

Matthew R Dreher

Reed A Omary

Riad Salem

Robert J Lewandowski

Andrew C Larson

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the combination of Y radioembolization (Y90) and drug-eluting bead irinotecan (DEBIRI) microspheres in the VX2 rabbit model.

Materials And Methods: An initial dose finding study was performed in 6 White New Zealand rabbits to identify a therapeutic but subcurative dose of Y90. In total, 29 rabbits were used in four groups: Y90 treatment (n = 8), DEBIRI treatment (n = 6), Y90 + DEBIRI treatment (n = 7), and an untreated control group (n = 8). Hepatic toxicity was evaluated at baseline, 24 h, 72 h, 1 week, and 2 weeks. MRI tumor volume (TV) and enhancing tumor volume were assessed baseline and 2 weeks. Tumor area and necrosis were evaluated on H&E for pathology.

Results: Infused activities of 84.0-94.4 MBq (corresponding to 55.1-72.7 Gy) were selected based on the initial dose finding study. Infusion of DEBIRI after Y90 was technically feasible in all cases (7/7). Overall, 21/29 animals survived to 2 weeks, and the remaining animals had extrahepatic disease on necropsy. Liver transaminases were elevated with Y90, DEBIRI, and Y90 + DEBIRI compared to control at 24 h, 72 h, and 1 week post-treatment and returned to baseline by 2 weeks. By TV, Y90 + DEBIRI was the only treatment to show statistically significant reduction at 2 weeks compared to the control group (p = 0.012). The change in tumor volume (week 2-baseline) for both Y90 + DEBIRI versus control (p = 0.002) and Y90 versus control (p = 0.014) was significantly decreased. There were no statistically significant differences among groups on pathology.

Conclusion: Intra-arterial Y90 + DEBIRI was safe and demonstrated enhanced antitumor activity in rabbit VX2 tumors. This combined approach warrants further investigation.

Citing Articles

Use of X-Ray Fluorescence Microscopy for Studies on Research Models of Hepatocellular Carcinoma.

Paunesku T, Gordon A, White S, Harris K, Antipova O, Maxey E Front Public Health. 2021; 9:711506.

PMID: 34490194 PMC: 8417723. DOI: 10.3389/fpubh.2021.711506.

References

Wang Y, Yang L, Zhang J, Zhou M, Shen L, Deng W . Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells. Int J Oncol. 2018; 53(4):1667-1680. DOI: 10.3892/ijo.2018.4514. View

Tanaka T, Nishiofuku H, Hukuoka Y, Sato T, Masada T, Takano M . Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model. J Vasc Interv Radiol. 2014; 25(7):1037-1044.e2. DOI: 10.1016/j.jvir.2014.04.005. View

Braat A, Huijbregts J, Molenaar I, Borel Rinkes I, van den Bosch M, Lam M . Hepatic radioembolization as a bridge to liver surgery. Front Oncol. 2014; 4:199. PMC: 4115667. DOI: 10.3389/fonc.2014.00199. View

Salem R, Thurston K . Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006; 17(8):1251-78. DOI: 10.1097/01.RVI.0000233785.75257.9A. View

Sato K, Lewandowski R, Mulcahy M, Atassi B, Ryu R, Gates V . Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology. 2008; 247(2):507-15. DOI: 10.1148/radiol.2472062029. View

Van Hazel G, Heinemann V, Sharma N, Findlay M, Ricke J, Peeters M . SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2016; 34(15):1723-31. DOI: 10.1200/JCO.2015.66.1181. View

Martin R, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M . Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2010; 18(1):192-8. DOI: 10.1245/s10434-010-1288-5. View

Martin 2nd R, Scoggins C, Schreeder M, Rilling W, Laing C, Tatum C . Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015; 121(20):3649-58. DOI: 10.1002/cncr.29534. View

Gordon A, Uddin O, Riaz A, Salem R, Lewandowski R . Making the Case: Intra-arterial Therapy for Less Common Metastases. Semin Intervent Radiol. 2017; 34(2):132-139. PMC: 5453769. DOI: 10.1055/s-0037-1601852. View

10.

Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P . Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012; 32(4):1387-95. View

11.

Wasan H, Gibbs P, Sharma N, Taieb J, Heinemann V, Ricke J . First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3.... Lancet Oncol. 2017; 18(9):1159-1171. PMC: 5593813. DOI: 10.1016/S1470-2045(17)30457-6. View

12.

Taylor R, Tang Y, Victoria Gonzalez M, Stratford P, Lewis A . Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci. 2006; 30(1):7-14. DOI: 10.1016/j.ejps.2006.09.002. View

13.

Boivin G, Washington K, Yang K, Ward J, Pretlow T, Russell R . Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology. 2003; 124(3):762-77. DOI: 10.1053/gast.2003.50094. View

14.

Van Hazel G, Pavlakis N, Goldstein D, Olver I, Tapner M, Price D . Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 2009; 27(25):4089-95. DOI: 10.1200/JCO.2008.20.8116. View

15.

Gordon A, Gradishar W, Kaklamani V, Thuluvath A, Ryu R, Sato K . Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol. 2014; 25(10):1523-32, 1532.e1-2. PMC: 4720166. DOI: 10.1016/j.jvir.2014.07.007. View

16.

Braat M, Samim M, van den Bosch M, Lam M . The role of Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging. 2016; 4:283-295. PMC: 4960274. DOI: 10.1007/s40336-016-0172-0. View

17.

Flisikowska T, Merkl C, Landmann M, Eser S, Rezaei N, Cui X . A porcine model of familial adenomatous polyposis. Gastroenterology. 2012; 143(5):1173-1175.e7. DOI: 10.1053/j.gastro.2012.07.110. View

18.

Martin R, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic P . Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol. 2010; 33(5):960-6. DOI: 10.1007/s00270-010-9937-4. View

19.

Johnson R, Fleet J . Animal models of colorectal cancer. Cancer Metastasis Rev. 2012; 32(1-2):39-61. PMC: 3572245. DOI: 10.1007/s10555-012-9404-6. View

20.

Rao P, Pascale F, Seck A, Auperin A, Drouard-Troalen L, Deschamps F . Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. Cardiovasc Intervent Radiol. 2012; 35(6):1448-59. DOI: 10.1007/s00270-012-0343-y. View